As of Apr 28
| -0.10 / -2.02%|
The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +126.80% increase from the last price of 4.85.
The current consensus among 2 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.